This study clearly supports a role for IL-23/IL-17 axis in LN and indicates that this cytokine pathway can be useful as biomarkers for renal disease activity and for predicting response to immunosuppressive treatment, especially in patients with a membranous phenotype. Here, IL17A is linked to kidney disorder.